The Inaugural IVT-MGI Conference: Unveiling the Future of Omics and Genomic Technologies in Istanbul
11/3/23
Offline
Istanbul, Türkiye
Share
On November 3rd, Istanbul hosted the First IVT-MGI Conference, immersing us in the future of Omics.
Collaborating with our distributor, Invitrotek, MGI experts, and a vibrant community of researchers and professionals, the conference delved into MGI's DNBSEQ™ Technology. This provided invaluable insights into sequencing technology advancements, unveiling NGS platforms reshaping omics research.
The event offered a unique opportunity to connect with a diverse community of scientists and industry leaders. At the core was the realization that the future of genomics has arrived, poised to shape science and healthcare in unprecedented ways.
Discover more about MGI's innovative products and the groundbreaking technologies discussed at the conference: MGI Sequencers.
To relive highlights from the IVT-MGI 1st Conference, don't forget to check out more details on IVT-MGI and the attached video.
As we reflect on this enriching experience, we invite you to stay connected and keep pushing the boundaries of science with us. Exciting updates and opportunities await on this incredible journey!
On November 3rd, Istanbul hosted the First IVT-MGI Conference, immersing us in the future of Omics.
Collaborating with our distributor, Invitrotek, MGI experts, and a vibrant community of researchers and professionals, the conference delved into MGI's DNBSEQ™ Technology. This provided invaluable insights into sequencing technology advancements, unveiling NGS platforms reshaping omics research.
The event offered a unique opportunity to connect with a diverse community of scientists and industry leaders. At the core was the realization that the future of genomics has arrived, poised to shape science and healthcare in unprecedented ways.
Discover more about MGI's innovative products and the groundbreaking technologies discussed at the conference: MGI Sequencers.
To relive highlights from the IVT-MGI 1st Conference, don't forget to check out more details on IVT-MGI and the attached video.
As we reflect on this enriching experience, we invite you to stay connected and keep pushing the boundaries of science with us. Exciting updates and opportunities await on this incredible journey!
On November 3rd, Istanbul hosted the First IVT-MGI Conference, immersing us in the future of Omics.
Collaborating with our distributor, Invitrotek, MGI experts, and a vibrant community of researchers and professionals, the conference delved into MGI's DNBSEQ™ Technology. This provided invaluable insights into sequencing technology advancements, unveiling NGS platforms reshaping omics research.
The event offered a unique opportunity to connect with a diverse community of scientists and industry leaders. At the core was the realization that the future of genomics has arrived, poised to shape science and healthcare in unprecedented ways.
Discover more about MGI's innovative products and the groundbreaking technologies discussed at the conference: MGI Sequencers.
To relive highlights from the IVT-MGI 1st Conference, don't forget to check out more details on IVT-MGI and the attached video.
As we reflect on this enriching experience, we invite you to stay connected and keep pushing the boundaries of science with us. Exciting updates and opportunities await on this incredible journey!
On November 3rd, Istanbul hosted the First IVT-MGI Conference, immersing us in the future of Omics.
Collaborating with our distributor, Invitrotek, MGI experts, and a vibrant community of researchers and professionals, the conference delved into MGI's DNBSEQ™ Technology. This provided invaluable insights into sequencing technology advancements, unveiling NGS platforms reshaping omics research.
The event offered a unique opportunity to connect with a diverse community of scientists and industry leaders. At the core was the realization that the future of genomics has arrived, poised to shape science and healthcare in unprecedented ways.
Discover more about MGI's innovative products and the groundbreaking technologies discussed at the conference: MGI Sequencers.
To relive highlights from the IVT-MGI 1st Conference, don't forget to check out more details on IVT-MGI and the attached video.
As we reflect on this enriching experience, we invite you to stay connected and keep pushing the boundaries of science with us. Exciting updates and opportunities await on this incredible journey!
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About Invitrotek
Invitrotek, IVT is a sales & marketing company which is focused on molecular diagnostics and genetic testing market in Turkey. Established in January 2009, IVT aims to be in the process of building a healthier community and future with the help of its stakeholders in the Turkish healthcare value chain.
The team of employees brings the company’s core competency into existence with their market expertise and field knowledge. In the light of the fact that having a high-quality after-sales service is among the important success factors in the Turkish IVD market, IVT has a well-experienced product support and technical service department and put a training program into place for its sub-dealers.
Another important asset for the company is its established distribution network consisting of direct sales force and well-respected regional dealers. With the help of its well-established distribution network, IVT has the ability to create high product penetration rates within a short term of marketing.
The company’s main product portfolio consists of NGS(Next Generation Sequencing) Systems from MGI, WES(Whole Exome Sequencing), CES(Clinical Exome Sequencing and Custom design NGS kits from Twist Bioscience, MLPA kits from MRC-Holland, NGS panels from NanodigmBio, line assays from Veinnalab, Drug Testing products from Siemens Healthineers, Immunochemistry products from Diasorin and controls for diagnostic testing form UTAK.
About Invitrotek
Invitrotek, IVT is a sales & marketing company which is focused on molecular diagnostics and genetic testing market in Turkey. Established in January 2009, IVT aims to be in the process of building a healthier community and future with the help of its stakeholders in the Turkish healthcare value chain.
The team of employees brings the company’s core competency into existence with their market expertise and field knowledge. In the light of the fact that having a high-quality after-sales service is among the important success factors in the Turkish IVD market, IVT has a well-experienced product support and technical service department and put a training program into place for its sub-dealers.
Another important asset for the company is its established distribution network consisting of direct sales force and well-respected regional dealers. With the help of its well-established distribution network, IVT has the ability to create high product penetration rates within a short term of marketing.
The company’s main product portfolio consists of NGS(Next Generation Sequencing) Systems from MGI, WES(Whole Exome Sequencing), CES(Clinical Exome Sequencing and Custom design NGS kits from Twist Bioscience, MLPA kits from MRC-Holland, NGS panels from NanodigmBio, line assays from Veinnalab, Drug Testing products from Siemens Healthineers, Immunochemistry products from Diasorin and controls for diagnostic testing form UTAK.
About Invitrotek
Invitrotek, IVT is a sales & marketing company which is focused on molecular diagnostics and genetic testing market in Turkey. Established in January 2009, IVT aims to be in the process of building a healthier community and future with the help of its stakeholders in the Turkish healthcare value chain.
The team of employees brings the company’s core competency into existence with their market expertise and field knowledge. In the light of the fact that having a high-quality after-sales service is among the important success factors in the Turkish IVD market, IVT has a well-experienced product support and technical service department and put a training program into place for its sub-dealers.
Another important asset for the company is its established distribution network consisting of direct sales force and well-respected regional dealers. With the help of its well-established distribution network, IVT has the ability to create high product penetration rates within a short term of marketing.
The company’s main product portfolio consists of NGS(Next Generation Sequencing) Systems from MGI, WES(Whole Exome Sequencing), CES(Clinical Exome Sequencing and Custom design NGS kits from Twist Bioscience, MLPA kits from MRC-Holland, NGS panels from NanodigmBio, line assays from Veinnalab, Drug Testing products from Siemens Healthineers, Immunochemistry products from Diasorin and controls for diagnostic testing form UTAK.
About Invitrotek
Invitrotek, IVT is a sales & marketing company which is focused on molecular diagnostics and genetic testing market in Turkey. Established in January 2009, IVT aims to be in the process of building a healthier community and future with the help of its stakeholders in the Turkish healthcare value chain.
The team of employees brings the company’s core competency into existence with their market expertise and field knowledge. In the light of the fact that having a high-quality after-sales service is among the important success factors in the Turkish IVD market, IVT has a well-experienced product support and technical service department and put a training program into place for its sub-dealers.
Another important asset for the company is its established distribution network consisting of direct sales force and well-respected regional dealers. With the help of its well-established distribution network, IVT has the ability to create high product penetration rates within a short term of marketing.
The company’s main product portfolio consists of NGS(Next Generation Sequencing) Systems from MGI, WES(Whole Exome Sequencing), CES(Clinical Exome Sequencing and Custom design NGS kits from Twist Bioscience, MLPA kits from MRC-Holland, NGS panels from NanodigmBio, line assays from Veinnalab, Drug Testing products from Siemens Healthineers, Immunochemistry products from Diasorin and controls for diagnostic testing form UTAK.
INNOVATION
NGS
DNBSEQ
IVT-MGI
ISTANBUL
Share this article :
Share
Sep 10, 2024
MGI Tech Unveils its SEQ ALL landscape at the Future of Omics Conference
Discover insights from the "Future of Omics" event, where leading experts discussed innovations in genomics, proteomics, and metabolomics. Explore key takeaways on advancing research and technology, shaping the future of personalized medicine and healthcare. Join us in celebrating the progress in omics!
Jun 1, 2024
MGI Tech Shares New Data on Core DNEBSEQ Technology and Showcases Latest Sequencing Innovations at ESHG 2024
MGI showcased its latest innovations at the ESHG 2024, highlighting the upgraded StandardMPS 2.0 sequencing chemistry and unveiling the new DNBelab C-TaiM 4 Single-Cell Droplet Generator. European researchers presented advancements in diagnostics, population health, and more.
Apr 27, 2024
MGI Showcases New DNBSEQ-E25 Sequencer & Partners with ABL Diagnostics at ESCMID Global 2024
MGI introduced its portable DNBSEQ-E25 sequencer at ESCMID Global 2024, designed for mobile and efficient genomic sequencing with applications in infectious diseases. Additionally, MGI announced a partnership with ABL Diagnostics to integrate DeepChek® assays into its platforms, broadening NGS solutions for microbiology labs.
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).